scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
September 01, 2021 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021 07:00 ET
|
scPharmaceuticals, Inc.
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on track...
scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study
July 13, 2021 16:08 ET
|
scPharmaceuticals, Inc.
Reduced average 30-day heart failure related costs by $17,753 (p<0.0001) per study subject in FUROSCIX® arm compared to historically matched comparators Study halted early due to highly...
scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®
July 01, 2021 08:00 ET
|
scPharmaceuticals, Inc.
FDA and Company in alignment on the path forward No additional clinical data or device modifications required at this time FUROSCIX NDA resubmission targeted for Q4 2021 BURLINGTON,...
scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 19, 2021 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
May 12, 2021 08:00 ET
|
scPharmaceuticals, Inc.
FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE...
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 23, 2021 07:00 ET
|
scPharmaceuticals, Inc.
FUROSCIX® New Drug Application resubmission anticipated in Q3 2021 FREEDOM clinical study on track for topline results in Q3 2021 Ended Q4 with cash, cash equivalents, restricted cash and...
scPharmaceuticals to Present in Two Upcoming Investor Conferences
February 25, 2021 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
February 23, 2021 08:00 ET
|
scPharmaceuticals, Inc.
No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million, sufficient to fund operations...
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors
February 17, 2021 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...